Cell Stem Cell 2017-06-01

From Cell Stem Cell to Clinical Trials: The Biotech Journey of Two Papers

Diana Crow

Index: 10.1016/j.stem.2017.05.013

Full Text: HTML

Abstract

How many of the authors who publish in Cell Stem Cell dream that their work will eventually wind up in the clinic? Probably quite a few. In the 10 years since its launch, Cell Stem Cell has featured many innovative discoveries, and several of them have gone on to become the seeds of burgeoning biotechnology companies with therapeutic aspirations. Two scientists who have seen that happen are Benjamin Reubinoff (Figure 1Figure 1) and Derrick Rossi (Figure 2Figure 2), both of whom led the clinical translation of technologies that made their public debut in Cell Stem Cell.

Latest Articles:

ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells

2017-07-13

[10.1016/j.stem.2017.06.004]

Lineage Tracing: Papers and Progress

2017-07-06

[10.1016/j.stem.2017.06.015]

Intestinal Enteroendocrine Lineage Cells Possess Homeostatic and Injury-Inducible Stem Cell Activity

2017-07-06

[10.1016/j.stem.2017.06.014]

Direct Neuronal Reprogramming: Achievements, Hurdles, and New Roads to Success

2017-07-06

[10.1016/j.stem.2017.06.011]

Making HSCs on Demand: Looking Ahead

2017-07-06

[10.1016/j.stem.2017.06.010]

More Articles...